Education
About Us
Working with TipRanks
Follow Us
Shanghai Henlius Biotech, Inc. Class H (HK:2696)
:2696
2696 Stock Chart & Stats
HK$58.60
HK$0.05(0.21%)
At close: 4:00 PM EST
HK$58.60
HK$0.05(0.21%)
Day’s Range― - ―
52-Week RangeHK$23.00 - HK$92.00
Previous CloseN/A
Volume849.10K
Average Volume (3M)1.53M
Market Cap
HK$24.59B
Enterprise ValueHK$35.28B
Total Cash (Recent Filing)HK$972.50M
Total Debt (Recent Filing)HK$3.67B
Price to Earnings (P/E)33.5
Beta0.32
Next Earnings
Mar 20, 2026EPS Estimate
0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.82
Shares Outstanding346,074,400
10 Day Avg. Volume1,665,497
30 Day Avg. Volume1,532,406
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)4.01
Price to Sales (P/S)2.11
P/FCF Ratio29.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)3.48
Revenue Forecast (FY)HK$7.11B
Bulls Say, Bears Say
Bulls Say
Profitability & MarginsHenlius has converted past losses into sustained profitability with a 73.1% gross margin and a 14.3% net margin in 2024. Durable high margins indicate strong pricing power and product mix, supporting ongoing R&D funding and commercialization without eroding unit economics.
Free Cash Flow & Cash ConversionA turnaround to positive free cash flow (404M) and OCF/Net Income >1 shows the business now generates real cash from operations. Durable cash generation reduces reliance on external financing and supports reinvestment, partnership commitments, and potential bolt-on activities.
Diversified Revenue Model & PartnershipsHenlius benefits from a multi-channel revenue model and meaningful partnerships that broaden market access and share development/commercial costs. Structurally this lowers single-market exposure, accelerates distribution, and supports steady revenue streams as new assets commercialize.
Bears Say
Higher LeverageA D/E of 1.21 and declining equity ratio indicate meaningful reliance on debt financing. Persistently higher leverage can constrain strategic flexibility, increase interest expense sensitivity, and limit ability to finance large R&D or commercialization investments without raising additional capital.
Modest Recent Revenue GrowthWhile profitability has improved, reported revenue growth of ~2.6% suggests top-line expansion is modest. Without faster organic growth or new product approvals/geographic expansion, margin gains may be driven by cost or pricing effects rather than sustainable volume growth.
Limited Investor Disclosure & GuidanceThe absence of earnings call details and notable corporate events reduces visibility into pipeline timing, regulatory milestones and commercialization pacing. Limited forward guidance hampers investors' ability to assess durable revenue drivers and execution risk over the next several quarters.
Shanghai Henlius Biotech, Inc. Class H News
2696 FAQ
What was Shanghai Henlius Biotech, Inc. Class H’s price range in the past 12 months?
Shanghai Henlius Biotech, Inc. Class H lowest stock price was HK$23.00 and its highest was HK$92.00 in the past 12 months.
What is Shanghai Henlius Biotech, Inc. Class H’s market cap?
Shanghai Henlius Biotech, Inc. Class H’s market cap is HK$24.59B.
When is Shanghai Henlius Biotech, Inc. Class H’s upcoming earnings report date?
Shanghai Henlius Biotech, Inc. Class H’s upcoming earnings report date is Mar 20, 2026 which is in 2 days.
How were Shanghai Henlius Biotech, Inc. Class H’s earnings last quarter?
Shanghai Henlius Biotech, Inc. Class H released its earnings results on Aug 25, 2025. The company reported HK$0.818 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.818.
Is Shanghai Henlius Biotech, Inc. Class H overvalued?
According to Wall Street analysts Shanghai Henlius Biotech, Inc. Class H’s price is currently Overvalued.
Does Shanghai Henlius Biotech, Inc. Class H pay dividends?
Shanghai Henlius Biotech, Inc. Class H does not currently pay dividends.
What is Shanghai Henlius Biotech, Inc. Class H’s EPS estimate?
Shanghai Henlius Biotech, Inc. Class H’s EPS estimate is 0.62.
How many shares outstanding does Shanghai Henlius Biotech, Inc. Class H have?
Shanghai Henlius Biotech, Inc. Class H has 346,074,400 shares outstanding.
What happened to Shanghai Henlius Biotech, Inc. Class H’s price movement after its last earnings report?
Shanghai Henlius Biotech, Inc. Class H reported an EPS of HK$0.818 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -4.132%.
Which hedge fund is a major shareholder of Shanghai Henlius Biotech, Inc. Class H?
Currently, no hedge funds are holding shares in HK:2696
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Henlius Biotech, Inc. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
217.03%
12-Months-Change
Fundamentals
Return on Equity
25.67%
Trailing 12-Months
Asset Growth
18.00%
Trailing 12-Months
Company Description
Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc., a biopharmaceutical company, engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating non-hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection to treat metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. The company also develops Serplulimab to treat squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, metastatic esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, nsNSCLC, squamous cell carcinoma of the head and neck (SCCHN), and solid tumors; HLX04-O, a bevacizumab injection for wet age-related macular degeneration; HLX22 to treat breast and metastatic gastric cancer; HLX07, HLX23, HLX35, HLX208, HLX55, HLX301, and HLX20 for the treatment of solid tumors; HLX11 to treat breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; HLX12 for gastric cancer, metastatic non-small cell lung cancer, and mCRC; and HLX14 to treat osteoporosis. In addition, it develops HLX26 for the treatment of solid tumor and lymphoma; HLX13 to treat melanoma, renal cell carcinoma, and mCRC; HLX15 for multiple myeloma; and HLX71 to treat COVID-19. Shanghai Henlius Biotech, Inc. operates in Mainland China, Europe, rest of Asia Pacific, and internationally. The company was founded in 2010 and is headquartered in Shanghai, China. Shanghai Henlius Biotech, Inc. is a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Technical Analysis
Zai Lab Ltd
―
InnoCare Pharma Ltd.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Simcere Pharmaceutical Group Limited
―
Ascentage Pharma Group International
―
Options Prices
Currently, No data available
---